Key Highlights

  • Filana Therapeutics (FLNA) is renamed Cassava Sciences, Inc. (formerly NASDAQ: SAVA), effective March 11, 2026, after two failed Alzheimer's Phase 3 trials for simufilam.
  • Yale's Bordey lab, in a 2020 Science Translational Medicine paper cited by the company, found simufilam cut seizure frequency 60% versus vehicle in a mouse model of focal onset seizures.
  • A newer, more severe TSC mouse model study, published in Epilepsia in April 2026, showed dose-dependent attenuation of seizure worsening without a restated percentage figure.
  • The FDA placed a full clinical hold on simufilam's TSC-epilepsy IND in December 2025; no human trial has started.

Filana Therapeutics, (NASDAQ:FLNA) the company formerly known as Cassava Sciences, is rebuilding around simufilam as a possible treatment for tuberous sclerosis complex-related epilepsy after the drug's Alzheimer's program collapsed in Phase 3. Early mouse data look encouraging, but an FDA clinical hold means no patient has yet been dosed for this new indication.

Why This Small-Cap Biotech Is Back in Focus

Filana Therapeutics, Inc. carries a corporate history biotech investors will recognize under a different name. Until March 11, 2026, it traded as Cassava Sciences, Inc. under ticker SAVA. A March 10, 2026 SEC filing announced the rebrand, and the stock began trading as FLNA on Nasdaq the next day. SEC EDGAR lists the registrant's Central Index Key as 0001069530 under both names, confirming one continuous entity.

The rebrand followed the collapse of Cassava's marquee asset. Simufilam, an oral small molecule described as a filamin A modulator, was tested for Alzheimer's disease in two Phase 3 studies, RETHINK-ALZ and REFOCUS-ALZ. A March 25, 2025 release disclosed that REFOCUS-ALZ "did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo," later confirmed for both studies by a January 2026 peer-reviewed paper. As that program wound down, the company pivoted toward TSC-related epilepsy, a drug-resistant epilepsy tied to a genetic mTOR-pathway disorder affecting roughly 45,000 people in the U.S., per company disclosures citing the TSC Alliance.

Legal baggage persists. A February 19, 2026 release confirmed the DOJ's Fraud Section closed its research-misconduct inquiry after the related indictment in United States v. Wang was dismissed with prejudice on October 23, 2025, and disclosed a September 2024 SEC settlement over "negligence-based disclosure" charges. In December 2025, the company agreed to pay $31.25 million to resolve a shareholder securities class action tied to a 2021 lawsuit covering trading between September 2020 and October 2023, without admitting wrongdoing.

From Alzheimer's Failure to Filana's (FLNA) Rare Epilepsy Bet

Filana's single disclosed focus now is simufilam for TSC-related epilepsy. The rationale traces to work by Angélique Bordey, PhD, at Yale School of Medicine, who has since joined the company as SVP, Neuroscience. Her research, published in Neuron (2014) and Science Translational Medicine (2020), examined how filamin A overexpression drives abnormal neuronal patterning in TSC. A November 12, 2025 release states this Yale work "showed treatment with simufilam alleviated neuronal abnormalities and reduced seizure frequency by 60% compared to vehicle in a mouse model of focal onset seizures." That figure is traceable to the 2020 paper, but it predates Filana's current strategy by years and came from a milder model than the company's newest study.

That newer work, run with the TSC Alliance's Preclinical Consortium and PsychoGenics, Inc., used the Tsc1 knockout mouse, an "exceptionally severe and progressive model" of the disease. Results published in Epilepsia on April 14, 2026 showed simufilam "attenuated the progression of seizure activity compared to vehicle, with a statistically significant correlation between simufilam dose and the number of seizures," without a restated percentage figure. Filana presented the program at Eilat XVIII in Madrid on May 5, 2026.

Regulatory Reality Check: A Clinical Hold, Not a Clinical Trial

No patient has been dosed with simufilam for TSC-related epilepsy. The March 12, 2026 release disclosed that the FDA issued a Clinical Hold Letter in December 2025 on the IND for this indication. As of May 7, 2026, the company remained "focused on generating the necessary data to resolve the FDA's Clinical Hold," including additional preclinical data and protocol changes, with an update expected "in the coming months" but no firm date given. Before the hold, the company had guided toward a proof-of-concept study in the first half of 2026: a timeline now overtaken by the setback.

Financial Position: A Shrinking Cash Cushion

Cash and equivalents stood at $86.6 million at March 31, 2026, down from $95.5 million at year-end 2025 and $128.6 million at year-end 2024, with no debt. Guidance calls for $47-50 million by June 30, 2026, reflecting an estimated $31.25 million litigation payment plus operating cash use of $14-17 million for the first half. First-quarter R&D fell 67% to $4.5 million; G&A fell to $6.6 million from $10.9 million. Net loss was $10.3 million, or $0.21 per share, versus $23.4 million a year earlier. Full-year 2025 net loss totaled $91.0 million, or $1.88 per share, versus $24.3 million in 2024, a swing driven mainly by a one-time $108.1 million non-cash warrant-revaluation gain in 2024. Shares outstanding stood at 48.3 million as of May 4, 2026.

Growth Path and Near-Term Milestones

Near-term catalysts are regulatory and scientific, since simufilam remains unapproved. The key milestone is resolving the FDA's clinical hold, needed before any proof-of-concept study can begin. Management also points to favorable human safety data from its roughly 1,929-patient Alzheimer's Phase 3 program as a potential asset for future TSC studies.

Material Company-Specific Risks

The most immediate risk is regulatory: the clinical hold means the case rests on an unresolved agency review outside the company's control. A second is scientific translation: the widely cited 60% figure comes from an older, milder model, while the newer, more relevant model has shown only a dose-dependent, non-quantified attenuation, and preclinical results often fail to replicate in humans, as simufilam's Alzheimer's program illustrates. A third is cash runway: with cash expected near $47-50 million by mid-year, there is limited room for setbacks before a capital raise or spending cuts. Reputational risk also lingers from the Cassava era.

Outlook

In an upside scenario, Filana satisfies the FDA's requests, the hold lifts, and the company starts a proof-of-concept study using cash preserved through the wind-down. Human data extending the Tsc1 model's dose-dependent effects would give the company a differentiated mechanism where, by its own account, over 60% of patients remain refractory to existing therapies.

In a base case, hold resolution drags further into 2026, consuming cash and delaying dosing. In a downside case, the FDA requires more work than the company's runway allows, forcing a capital raise, cost cuts, or reassessment: underscored by this drug's earlier failure to translate from preclinical promise to human efficacy, in Alzheimer's disease. This article offers no view on where FLNA shares might trade.

Conclusion

Filana Therapeutics, Inc. (FLNA) is attempting a genuine second act for simufilam, moving from a failed Alzheimer's program to a rare epilepsy indication backed by preclinical data from Yale researchers and the TSC Alliance. The 60% seizure-reduction figure anchoring the narrative comes from an earlier, milder mouse model published in 2020; the newer, more severe model has shown only a dose-dependent trend without a comparable statistic. With an FDA clinical hold unresolved and cash declining, Filana's path to a clinical answer for TSC-related epilepsy remains an open question.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.